论文部分内容阅读
目的分析对慢性乙肝恩替卡韦经治患者实施联合聚乙二醇干扰素的临床疗效。方法对于应用恩替卡韦治疗3年以上,持续HBV-DNA阴性,无法实现e抗原血清学转换的e抗原阳性慢乙肝患者,总样本50例,随机分为2组,1组26例为继续单用恩替卡韦,另1组24例为恩替卡韦加用聚乙二醇干扰素。两组患者治疗1年后观察e抗原消失和血清学转换率。结果相比对照组,观察组患者的临床疗效明显更佳,差异有统计学意义(P<0.05)。结论恩替卡韦经治患者,加用干扰素联合治疗,可以使更多的患者出现e抗原,甚至s抗原血清学转换,从而达到停药标准。
Objective To analyze the clinical effect of combined pegylated interferon on patients with chronic hepatitis B entecavir. Methods 50 patients with e antigen-positive chronic hepatitis B who were treated with entecavir for more than 3 years and who had persistent HBV-DNA negative and could not achieve e antigen seroconversion, were randomly divided into 2 groups. One group of 26 patients were enrolled with entecavir , Another group of 24 cases of entecavir plus pegylated interferon. After two years of treatment, the e antigen disappearance and seroconversion rate were observed in both groups. Results Compared with the control group, the clinical efficacy of observation group was significantly better, the difference was statistically significant (P <0.05). Conclusion Entecavir treated patients, combined with interferon treatment, can make more patients with e antigen, or even s antigen seroconversion, so as to achieve the withdrawal criteria.